Clinical Trials on Hyperoxaluria in Finland

Total 6 results

Allena Pharmaceuticals

Completed

Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Hyperoxaluria and Kidney Stones

Nephrolithiasis | Kidney Stones | Hyperoxaluria | Secondary Hyperoxaluria | Dietary Hyperoxaluria

United States
Allena Pharmaceuticals

Completed

Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Secondary Hyperoxaluria and Kidney Stones Over 28 Days

Nephrolithiasis | Kidney Stones | Hyperoxaluria | Secondary Hyperoxaluria | Dietary Hyperoxaluria

United States
Allena Pharmaceuticals

Completed

A Pilot Study of Oxalate Absorption in Secondary Hyperoxaluria

Nephrolithiasis | Kidney Stones | Hyperoxaluria | Secondary Hyperoxaluria

United States
Allena Pharmaceuticals

Completed

Evaluating ALLN-177 for Reducing Urinary Oxalate Excretion in Calcium Oxalate Kidney Stone Formers With Hyperoxaluria

Nephrolithiasis | Hyperoxaluria

United States
Novome Biotechnologies Inc

Terminated

Safety, Tolerability, and Pharmacodynamics of NOV-001 in Adult Subjects

Healthy Volunteers | Enteric Hyperoxaluria

United States, Canada
Allena Pharmaceuticals

Terminated

Establishing the Safety and Efficacy of Reloxaliase in Patients With Enteric Hyperoxaluria (URIROX-2)

Enteric Hyperoxaluria

United States, Spain, United Kingdom, Portugal, Romania, Canada, Austria, Belgium, Brazil, Croatia, France, Germany, Italy, Mexico, Russian Federation, Switzerland

3

Subscribe